Jyong Biotech (MENS) Other Accumulated Expenses (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Other Accumulated Expenses of $32000.0 for Q4 2025, down 5.88% year-over-year from $34000.0 in Q4 2024, and down 99.05% quarter-over-quarter from $3.4 million in Q2 2025.
Jyong Biotech (MENS) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Jyong Biotech's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $32000.0 for Q4 2025.
- In Q4 2025, Other Accumulated Expenses fell 5.88% year-over-year to $32000.0; the TTM figure through Dec 2025 stood at $32000.0 (down 5.88% YoY), while the FY2025 annual figure was $32000.0, down 5.88% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $32000.0, down from $3.4 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $3.4 million in Q2 2025, with the low at $32000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jyong Biotech | 159.89 Mn | 159.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32,000.00 |
| Jun 30, 2025 | 3.37 Mn |
| Dec 31, 2024 | 34,000.00 |